Tina Jorsal1, Nicolai A Rhee1,2, Jens Pedersen3,4, Camilla D Wahlgren1, Brynjulf Mortensen1,5, Sara L Jepsen3,4, Jacob Jelsing6, Louise S Dalbøge6,7, Peter Vilmann8,9, Hazem Hassan8,9, Jakob W Hendel8,9, Steen S Poulsen3,4, Jens J Holst3,4, Tina Vilsbøll1,10,11, Filip K Knop12,13,14. 1. Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900, Hellerup, Denmark. 2. Novo Nordisk A/S, Bagsværd, Denmark. 3. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 4. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 5. Chr. Hansen A/S, Hørsholm, Denmark. 6. Gubra ApS, Hørsholm, Denmark. 7. Novo Nordisk Research Center, Seattle, WA, USA. 8. Endoscopic Unit, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 9. Gastrounit, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark. 10. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 11. Steno Diabetes Center Copenhagen, University of Copenhagen, Gentofte, Denmark. 12. Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, DK-2900, Hellerup, Denmark. filipknop@dadlnet.dk. 13. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. filipknop@dadlnet.dk. 14. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. filipknop@dadlnet.dk.
Abstract
AIMS/HYPOTHESIS: Enteroendocrine K and L cells are pivotal in regulating appetite and glucose homeostasis. Knowledge of their distribution in humans is sparse and it is unknown whether alterations occur in type 2 diabetes. We aimed to evaluate the distribution of enteroendocrine K and L cells and relevant prohormone-processing enzymes (using immunohistochemical staining), and to evaluate the mRNA expression of the corresponding genes along the entire intestinal tract in individuals with type 2 diabetes and healthy participants. METHODS: In this cross-sectional study, 12 individuals with type 2 diabetes and 12 age- and BMI-matched healthy individuals underwent upper and lower double-balloon enteroscopy with mucosal biopsy retrieval from approximately every 30 cm of the small intestine and from seven specific anatomical locations in the large intestine. RESULTS: Significantly different densities for cells positive for chromogranin A (CgA), glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, peptide YY, prohormone convertase (PC) 1/3 and PC2 were observed along the intestinal tract. The expression of CHGA did not vary along the intestinal tract, but the mRNA expression of GCG, GIP, PYY, PCSK1 and PCSK2 differed along the intestinal tract. Lower counts of CgA-positive and PC1/3-positive cells, respectively, were observed in the small intestine of individuals with type 2 diabetes compared with healthy participants. In individuals with type 2 diabetes compared with healthy participants, the expression of GCG and PYY was greater in the colon, while the expression of GIP and PCSK1 was greater in the small intestine and colon, and the expression of PCSK2 was greater in the small intestine. CONCLUSIONS/ INTERPRETATION: Our findings provide a detailed description of the distribution of enteroendocrine K and L cells and the expression of their products in the human intestinal tract and demonstrate significant differences between individuals with type 2 diabetes and healthy participants. TRIAL REGISTRATION: NCT03044860.
AIMS/HYPOTHESIS: Enteroendocrine K and L cells are pivotal in regulating appetite and glucose homeostasis. Knowledge of their distribution in humans is sparse and it is unknown whether alterations occur in type 2 diabetes. We aimed to evaluate the distribution of enteroendocrine K and L cells and relevant prohormone-processing enzymes (using immunohistochemical staining), and to evaluate the mRNA expression of the corresponding genes along the entire intestinal tract in individuals with type 2 diabetes and healthy participants. METHODS: In this cross-sectional study, 12 individuals with type 2 diabetes and 12 age- and BMI-matched healthy individuals underwent upper and lower double-balloon enteroscopy with mucosal biopsy retrieval from approximately every 30 cm of the small intestine and from seven specific anatomical locations in the large intestine. RESULTS: Significantly different densities for cells positive for chromogranin A (CgA), glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, peptide YY, prohormone convertase (PC) 1/3 and PC2 were observed along the intestinal tract. The expression of CHGA did not vary along the intestinal tract, but the mRNA expression of GCG, GIP, PYY, PCSK1 and PCSK2 differed along the intestinal tract. Lower counts of CgA-positive and PC1/3-positive cells, respectively, were observed in the small intestine of individuals with type 2 diabetes compared with healthy participants. In individuals with type 2 diabetes compared with healthy participants, the expression of GCG and PYY was greater in the colon, while the expression of GIP and PCSK1 was greater in the small intestine and colon, and the expression of PCSK2 was greater in the small intestine. CONCLUSIONS/ INTERPRETATION: Our findings provide a detailed description of the distribution of enteroendocrine K and L cells and the expression of their products in the human intestinal tract and demonstrate significant differences between individuals with type 2 diabetes and healthy participants. TRIAL REGISTRATION: NCT03044860.
Authors: J P Gutzwiller; B Göke; J Drewe; P Hildebrand; S Ketterer; D Handschin; R Winterhalder; D Conen; C Beglinger Journal: Gut Date: 1999-01 Impact factor: 23.059
Authors: Nicolai A Rhee; Camilla D Wahlgren; Jens Pedersen; Brynjulf Mortensen; Ebbe Langholz; Erik P Wandall; Steffen U Friis; Peter Vilmann; Sarah J Paulsen; Viggo B Kristiansen; Jacob Jelsing; Louise S Dalbøge; Steen S Poulsen; Jens J Holst; Tina Vilsbøll; Filip K Knop Journal: Diabetologia Date: 2015-07-18 Impact factor: 10.122
Authors: Ana D Stan; Subroto Ghose; Xue-Min Gao; Rosalinda C Roberts; Kelly Lewis-Amezcua; Kimmo J Hatanpaa; Carol A Tamminga Journal: Brain Res Date: 2006-10-12 Impact factor: 3.252
Authors: James T Patterson; Nickki Ottaway; Vasily M Gelfanov; David L Smiley; Diego Perez-Tilve; Paul T Pfluger; Matthias H Tschöp; Richard D Dimarchi Journal: ACS Chem Biol Date: 2010-11-04 Impact factor: 5.100
Authors: T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp Journal: Mol Metab Date: 2019-09-30 Impact factor: 7.422
Authors: Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney Journal: Rev Endocr Metab Disord Date: 2020-08-26 Impact factor: 6.514
Authors: Sara E Stinson; Anna E Jonsson; Morten A V Lund; Christine Frithioff-Bøjsøe; Louise Aas Holm; Oluf Pedersen; Lars Ängquist; Thorkild I A Sørensen; Jens J Holst; Michael Christiansen; Jens-Christian Holm; Bolette Hartmann; Torben Hansen Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Alexander Dimitri Miras; Anna Kamocka; Belén Pérez-Pevida; Sanjay Purkayastha; Krishna Moorthy; Ameet Patel; Harvinder Chahal; Gary Frost; Paul Bassett; Lidia Castagnetto-Gissey; Lucy Coppin; Nicola Jackson; Anne Margot Umpleby; Stephen Robert Bloom; Tricia Tan; Ahmed Rashid Ahmed; Francesco Rubino Journal: Diabetes Care Date: 2020-11-06 Impact factor: 19.112